New combo therapy for endometrial cancer tested in Real-World setting

NCT ID NCT06995833

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study is tracking the safety and effectiveness of durvalumab (with or without olaparib) in about 50 Korean patients with endometrial cancer who are already prescribed these drugs. Researchers will follow participants for up to 12 months to see how well the treatment works in everyday practice and what side effects occur. The goal is to confirm that the approved drug combination performs as expected outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
durvalumab with or without olaparib
What this could lead to
If successful, this study could confirm that durvalumab with or without olaparib works safely in everyday practice for endometrial cancer, supporting its continued use.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It is small (50 patients) and only follows people for 12 months, so long-term effects or rare side effects may be missed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.